COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Dec 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how effective a COVID-19 vaccine, specifically one booster dose targeting a variant called XBB, is at preventing repeated COVID-19 infections in lung cancer patients who are receiving cancer treatment. The researchers want to see if vaccinated patients have fewer instances of severe lung problems or even death compared to those who choose not to get vaccinated. Additionally, they will be checking blood samples to understand how well the vaccine works and to find the best timing for vaccinations.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with lung cancer, currently undergoing cancer treatments like chemotherapy or immunotherapy, and have a history of COVID-19 infection. If you decide to join, you’ll be closely monitored for any COVID-related health issues and your blood will be tested to measure your body’s response to the vaccine. It's important to know that people with certain health conditions or recent severe reactions to treatments may not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who agree to participate in the trial and sign the informed consents.
• • 2. Male or female, ≥18 years old.
• • 3. Diagnosed of lung carcinoma by histological and cytological examinations.
• • 4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.
• • 5. Recorded history of COVID19 infection.
• • 6. Sufficiently functional organs.
• • 7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2.
• Exclusion Criteria:
• • 1. Life expectance less than 3 months.
• • 2. Less than 3 months since last confirmed COVID-19 infection.
• • 3. Patients unable to return the hospital for follow-up.
• • 4. Patients allergic to COVID-19 vaccine.
• • 5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.